About the study

The purpose of this study is to determine if nivolumab added to the standard of care therapy (SOC) given after surgery is more effective than SOC alone in prolonging disease free survival in NSCLC participants with minimal residual disease detected after surgery.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

prior to Surgery:

1. Suspected or histologically confirmed Stage IIA to IIIB NSCLC with disease that is considered resectable
2. Must be deemed eligible for complete resection and must agree to undergo standard of care surgery for complete resection of NSCLC
3. Treatment naive (no previous systemic treatment)

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.